Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyShukra Pharmaceuticals Ltd 2CIN NO.L24231GJ1993PLC019079 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 4.17 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Arpita Kabra Designation: Company Secretary and Compliance Secretary EmailId: kabraarpita10@gmail.com Name of the Chief Financial Officer: Anar Jayesh Patel Designation: Chief Financial Officer EmailId: info@shukrapharmaceuticals.com Date: 29/04/2026 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Shukra Pharmaceuticals Ltd.

29 Apr 2026

33.66

1.91%

Board Meeting

Shukra Pharmaceuticals Ltd - 524632 - Board Meeting Intimation for Audited Financial Result For The Quarter …

BSE India

Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/05/2026 ,inter alia, to consider and approve Audited financial result for the quarter and financial year ended on 31st March, 2026 along with the Auditor''s Report

pdf

Shukra Pharmaceuticals Ltd.

08 Apr 2026

33.66

1.91%

Company Update

Shukra Pharmaceuticals Ltd - 524632 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Certificate under Reg 74(5)

pdf

Shukra Pharmaceuticals Ltd.

20 Mar 2026, 12:58PM

33.66

1.91%

SAST

Shukra Pharmaceuticals Ltd - 524632 - Closure of Trading Window

BSE India

Closure of Trading Window

pdf

Shukra Pharmaceuticals Ltd.

16 Mar 2026

33.66

1.91%

Board Meeting

Shukra Pharmaceuticals Ltd - 524632 - Board Meeting Outcome for Independent Directors Meeting

BSE India

Independent Directors Meeting

pdf

Shukra Pharmaceuticals Ltd.

06 Mar 2026

33.66

1.91%

Board Meeting

Shukra Pharmaceuticals Ltd - 524632 - Board Meeting Intimation for Independent Directors Meeting

BSE India

Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/03/2026 ,inter alia, to consider and approve Independent Directors Meeting

pdf